Lumexa Imaging (NASDAQ:LMRI) Issues FY 2026 Earnings Guidance

Lumexa Imaging (NASDAQ:LMRI) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided EPS guidance of 0.710-0.770 for the period, compared to the consensus EPS estimate of 0.650. The company issued revenue guidance of $1.0 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Lumexa Imaging Stock Up 1.0%

LMRI stock opened at $7.78 on Friday. The company has a 50 day moving average of $9.15. Lumexa Imaging has a twelve month low of $6.45 and a twelve month high of $19.45.

Wall Street Analysts Forecast Growth

LMRI has been the subject of several research analyst reports. Weiss Ratings initiated coverage on Lumexa Imaging in a research note on Wednesday, May 13th. They set a “sell (e-)” rating for the company. Raymond James Financial upgraded Lumexa Imaging from an “outperform” rating to a “strong-buy” rating and set a $23.00 target price for the company in a research note on Monday, February 9th. Finally, Barclays reduced their target price on Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating for the company in a research note on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Lumexa Imaging currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Insider Transactions at Lumexa Imaging

In other news, Director Brett Brodnax purchased 35,000 shares of Lumexa Imaging stock in a transaction that occurred on Tuesday, May 19th. The stock was acquired at an average cost of $7.25 per share, for a total transaction of $253,750.00. Following the purchase, the director directly owned 62,027 shares of the company’s stock, valued at $449,695.75. This trade represents a 129.50% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.70% of the stock is owned by company insiders.

Institutional Trading of Lumexa Imaging

Several institutional investors have recently added to or reduced their stakes in LMRI. Geode Capital Management LLC bought a new stake in Lumexa Imaging in the 4th quarter valued at $1,548,000. Goldman Sachs Group Inc. bought a new stake in shares of Lumexa Imaging during the 4th quarter valued at $18,870,000. TD Asset Management Inc bought a new stake in shares of Lumexa Imaging during the 4th quarter valued at $1,264,000. JPMorgan Chase & Co. bought a new stake in shares of Lumexa Imaging during the 4th quarter valued at $15,954,000. Finally, Federated Hermes Inc. bought a new stake in shares of Lumexa Imaging during the 4th quarter valued at $8,325,000.

Lumexa Imaging Company Profile

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).